Archive position — measured, not model output
1 like on Devpost
506 of the 7,856 archived projects have more likes, and 1,758 share exactly 1 — so this project's #1,439 place in the like-ranked listing is a tie-break inside that group, not a ranking.
Projects (log scale)
Likes on Devpost. ▲ marks this project's group.
Show the figures
| Likes | Projects | Share of archive |
|---|---|---|
| 0 | 5,592 | 71.2% |
| 1 | 1,758 | 22.4% |
| 2 | 285 | 3.6% |
| 3–4 | 132 | 1.7% |
| 5–9 | 75 | 1.0% |
| 10+ | 14 | 0.2% |
Executive Summary
What the company appears to be
MeguPon is a self-reported personal health app for glaucoma patients, built by a single developer (lalalatang Tanaka) using AI tools including Codex and GPT-5.6 Sol. It tracks eye-drop medication timing using rhythm bands to visualize dosing clusters.
What changed
The author reports building the core feature — "Timing Rhythm Bands" — in one session with Codex + GPT-5.6 Sol, including bug fixes for time clustering and midnight wrap-around logic.
Single most important open question
Is there any evidence of user adoption or market traction beyond the single developer's personal use?
What The Product Actually Is
The description states that MeguPon is an iPhone app (SwiftUI/SwiftData) designed to track glaucoma eye-drop medications. It features "Timing Rhythm Bands" which show when drops actually happen, using median and interquartile range (IQR) for each medication.
The app displays dosing clusters: morning and evening meds are shown separately. The design principle is to present only facts, without scores, advice or warning colors — judgment stays with the patient and their doctor.
The author reports that the app was approved for App Store distribution in July 2026.
Evidence
- Built with iOS technologies (SwiftUI, SwiftData)
- Tracks eye-drop timing using rhythm bands
- Uses median + IQR to show dosing clusters
- Approved for App Store in July 2026
Inference
- The app is a personal health tracking tool for glaucoma patients
- It uses AI-assisted development (Codex + GPT-5.6 Sol)
Positioning & Claim Evolution
The author positions MeguPon as a patient-built solution to a personal problem — managing daily eye-drop medications for glaucoma.
The tagline is: "Eye-drop rhythm tracker for glaucoma patients — built by a patient, with Codex + GPT-5.6 Sol."
The project description claims that the app was built entirely using AI tools (Codex + GPT-5.6 Sol), including planning, implementation and bug fixing.
Evidence
- Tagline: "Eye-drop rhythm tracker for glaucoma patients — built by a patient, with Codex + GPT-5.6 Sol"
- The app was built using AI tools (Codex + GPT-5.6 Sol)
- The core feature was implemented in one session
Inference
- The positioning is personal and niche: addressing a specific medical need
- The claim of AI-assisted development may be aspirational or self-reported, not verified
Target Customer & ICP
The description states that the app is built for glaucoma patients who take eye drops daily. It was designed by someone with personal experience of the condition.
Evidence
- Built for glaucoma patients
- Personal use case: author has glaucoma and diagnosed in early 30s
Inference
- The target customer is likely a subset of glaucoma patients who are tech-savvy or self-manage their medication
- No evidence of broader market targeting or segmentation
Business Model & Pricing Evidence
There is no evidence of pricing, monetization or business model in the description.
Evidence
- Not evidenced
Inference
- The app appears to be a personal tool with no stated revenue model
- It was submitted to a hackathon and not described as a commercial product
Technical & Delivery Signals
The author reports building the app using Swift, SwiftUI, SwiftData, NFC, and iOS development tools. The core feature — "Timing Rhythm Bands" — was implemented using Codex + GPT-5.6 Sol.
The project includes bug fixes for time clustering and midnight wrap-around logic, which were resolved in one pass with AI assistance.
Evidence
- Built with Swift, SwiftUI, SwiftData, NFC
- Core feature built with Codex + GPT-5.6 Sol
- Bug fixes handled by AI (time clustering, midnight wrap-around)
Inference
- The app is technically feasible and uses modern iOS development practices
- AI tools were used for rapid prototyping and implementation
Traction & Maturity Signals
The description states that the app was approved for App Store distribution in July 2026. It also mentions that it was built using Codex sessions since June 2026, but no evidence of user adoption or usage metrics is provided.
Evidence
- Approved for App Store in July 2026
- Built with Codex sessions since June 2026
Inference
- The app exists and has been released
- No evidence of user engagement, downloads, or feedback
Competitive Context
There is no evidence of competitors or market context provided in the description.
Evidence
- Not evidenced
Inference
- The app may be a niche tool for glaucoma patients
- No known comparable products are mentioned
Key Risks & Red Flags
- No user data or adoption metrics: The only evidence of use is from the single developer.
- Unverified claims: The AI-assisted development and feature implementation are self-reported without independent verification.
- Single-person team: Limited capacity for scaling or iteration.
- Personal project: Not a commercial product with clear market demand.
Evidence
- No user data, adoption, or revenue
- No third-party validation of AI claims
- Single developer (lalalatang Tanaka)
Diligence Questions To Ask The Founders
- What is the actual user base for MeguPon? Is it used by others beyond the author?
- How does the app handle data privacy and compliance with health regulations?
- Are there any plans to expand functionality or monetize the product?
- Can you provide evidence of how the AI tools (Codex + GPT-5.6 Sol) were used in practice, not just claimed?
- What is the long-term vision for MeguPon beyond personal use?
Investment/Partnership Verdict
The description presents a self-reported personal project with no verified traction or commercial evidence. The app exists and was approved for App Store distribution, but there is no indication of user adoption, revenue or market demand.
Evidence
- App exists and is approved
- No evidence of users, revenue, or commercialization
Inference
- Not a viable investment or partnership opportunity based on this description alone
- The project may be a prototype or personal tool with limited commercial potential
Source
Submitted to the OpenAI 2026 hackathon on Devpost. Project home on DevPost.
The analysis above was generated by a language model from the project's own one-line description. It is not independent research and contains no verified traction, revenue or customer data.